Clinical value of LncRNA MEG3 in high-grade serous ovarian cancer

Marianna Buttarelli, Maria De Donato, Giuseppina Raspaglio, Gabriele Babini, Alessandra Ciucci, Enrica Martinelli, Pina Baccaro, Tina Pasciuto, Anna Fagotti, Giovanni Scambia, Daniela Gallo

Research output: Contribution to journalArticle

7 Citations (Scopus)


Long non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade serous ovarian cancer (HGSOC), the most common and deadliest gynecologic malignancy. To the aim of the study, we measured MEG3 transcript levels in 90 pre-treatment peritoneal biopsies. We also investigated MEG3 function in ovarian cancer biology. We found that high MEG3 expression was independently associated with better progression-free (p = 0.002) and overall survival (p = 0.01). In vitro and in vivo preclinical studies supported a role for MEG3 as a tumor suppressor in HGSOC, possibly through modulation of the phosphatase and tensin homologue (PTEN) network. Overall, results from this study demonstrated that decreased MEG3 is a hallmark for malignancy and tumor progression in HGSOC.
Original languageEnglish
Pages (from-to)1-19
Number of pages19
Publication statusPublished - 2020


  • Cancer biomarkers
  • LncRNAs
  • MEG3
  • Ovarian cancer cell lines
  • Ovary
  • Overall survival
  • Personalized medicine
  • Progression-free survival


Dive into the research topics of 'Clinical value of LncRNA MEG3 in high-grade serous ovarian cancer'. Together they form a unique fingerprint.

Cite this